Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.

Molecular cancer research : MCR - 1 Oct 2016

Ryan Meagan B, Finn Alexander J, Pedone Katherine H, Thomas Nancy E, Der Channing J, Cox Adrienne D

Abstract excerpt

Recently, we identified that PREX1 overexpression is critical for metastatic but not tumorigenic growth in a mouse model of NRAS-driven melanoma. In addition, a PREX1 gene signature correlated with and was dependent on ERK MAPK activation in human melanoma cell lines. In the current study, the underlying mechanism of PREX1 overexpression in human melanoma was assessed. PREX1 protein levels were increased in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases
Share to Guanine Nucleotide Exchange Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Piperazines

Share to Pyridones

Share to Pyrimidinones

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 27418645
DOI: 10.1158/1541-7786.MCR-16-0184
PMCID: PMC5065759

Genes

PREX1
NRAS
RAC1
BRAF
CDC42

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma.PMID 27418645Read ↗

Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.Semantic proximity Read ↗

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanomaSemantic proximity Read ↗

Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Semantic proximity Read ↗

Specific <i>SOX10</i> enhancer elements modulate phenotype plasticity and drug resistance in melanomaSemantic proximity Read ↗

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.Semantic proximity Read ↗

FRA1 drives melanoma metastasis through an actionable transcriptional networkSemantic proximity Read ↗

Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations.Semantic proximity Read ↗

Molecular pathways: P-Rex in cancer.Semantic proximity Read ↗

Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions.Semantic proximity Read ↗

Tumorigenesis driven by the BRAF <sup>V600E</sup> oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasionSemantic proximity Read ↗

Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach.Semantic proximity Read ↗

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.